Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients

• Status: Completed
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Vascular calcification (VC) represents one of the major complications associated with progressive renal impairment. Matrix Gla-protein (MGP) is a vitamin K-dependent protein that acts as a powerful inhibitor of vascular calcification. Despite this fact, it remains unknown whether supplementation with vitamin K can lead to reduction or reversal of vascular and heart valve calcification. Our study aims primarily to investigate the effect of intravenous vitamin K1 three times weekly for a total duration of 6 months on the serum levels of dephosphorylated-uncarboxylated MGP (dp-ucMGP) as well as aortic calcification score and severity of aortic and mitral valve lesions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Vitamin K; Vitamin K 1

Criteria

Inclusion Criteria:

• Males or females ≥18 years of age,

• Not less than 6 months on HD,

• High level of serum dephosphorylated uc-MGP

• Signed informed consent,

Exclusion Criteria:

• Patients with normal level of dp-ucMGP

• History of thrombosis,

• Intake of vitamin K antagonists (warfarin) at baseline or in the 3 months prior to baseline,

• Inflammatory bowel disease,

• Liver dysfunction,